-
GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice Neuropharmacology (IF 4.7) Pub Date : 2024-04-09 Cui Liu, Wen-Hong Liu, Wu Yang, Lei Chen, Yan Xue, Xin-Yi Chen
The spontaneous firing activity of nigral dopaminergic neurons is associated with some important roles including modulation of dopamine release, expression of tyrosine hydroxylase (TH), as well as neuronal survival. The decreased neuroactivity of nigral dopaminergic neurons has been revealed in Parkinson's disease. Central glucagon-like peptide-1 (GLP-1) functions as a neurotransmitter or neuromodulator
-
Pharmacological blockade of 2-AG degradation ameliorates clinical, neuroinflammatory and synaptic alterations in experimental autoimmune encephalomyelitis Neuropharmacology (IF 4.7) Pub Date : 2024-04-02 Livia Guadalupi, Georgia Mandolesi, Valentina Vanni, Sara Balletta, Silvia Caioli, Anto Pavlovic, Francesca De Vito, Diego Fresegna, Krizia Sanna, Laura Vitiello, Monica Nencini, Alice Tartacca, Fabrizio Mariani, Valentina Rovella, Sven Schippling, Iris Ruf, Ludovic Collin, Diego Centonze, Alessandra Musella
-
Exploring the effect of 6-BIO and sulindac in modulation of Wnt/β-catenin signaling pathway in chronic phase of temporal lobe epilepsy Neuropharmacology (IF 4.7) Pub Date : 2024-04-02 Vipasha Gautam, Kajal Rawat, Arushi Sandhu, Anil Kumar, Parampreet Singh Kharbanda, Bikash Medhi, Alka Bhatia, Lekha Saha
-
Ursolic acid molecules dock MAPK1 to modulate gut microbiota diversity to reduce neuropathic pain Neuropharmacology (IF 4.7) Pub Date : 2024-04-01 Zi-Jie Rong, Min Chen, Hong-Hua Cai, Gui-Hua Liu, Jin-Biao Chen, Hao Wang, Zhi-Wen Zhang, Yu-Liang Huang, Shuang-Fei Ni
To investigate the efficacy of Ursolic acid in alleviating neuropathic pain in rats with spinal nerve ligation (SNL), the SNL rat model was surgically induced. Different concentrations of Ursolic acid and manipulated target mitogen-activated protein kinase 1 (MAPK1) were administered to the SNL rats. Fecal samples were collected from each group of rats for 16S rDNA analysis to examine the impact of
-
The multifaceted role of Wnt canonical signalling in neurogenesis, neuroinflammation, and hyperexcitability in mesial temporal lobe epilepsy Neuropharmacology (IF 4.7) Pub Date : 2024-04-01 Priya, Nitin Yadav, Sneha Anand, Jyotirmoy Banerjee, Manjari Tripathi, P Sarat Chandra, Aparna Banerjee Dixit
Epilepsy is a neurological disorder characterised by unprovoked, repetitive seizures caused by abnormal neuronal firing. The Wnt/β–Catenin signalling pathway is involved in seizure-induced neurogenesis, aberrant neurogenesis, neuroinflammation, and hyperexcitability associated with epileptic disorder. Wnt/β–Catenin signalling is crucial for early brain development processes including neuronal patterning
-
NLRP3 inflammasome signalling in Alzheimer's disease Neuropharmacology (IF 4.7) Pub Date : 2024-03-31 Róisín M. McManus, Eicke Latz
-
4′-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms Neuropharmacology (IF 4.7) Pub Date : 2024-03-28 Maurício dos Santos Pereira, Gabriel Henrique Dias de Abreu, Leonardo Calaça Arruda Vanderlei, Rita Raisman-Vozari, Francisco Silveira Guimarães, Hui-Chen Lu, Patrick Pierre Michel, Elaine Del Bel
-
The dopamine D2-like receptor and the Y-chromosome gene, SRY, are reciprocally regulated in the human male neuroblastoma M17 cell line Neuropharmacology (IF 4.7) Pub Date : 2024-03-27 Dong-Hyun Kim, Hannah Loke, James Thompson, Rachel Hill, Suresh Sundram, Joohyung Lee
-
Exploring the role of ghrelin and des-acyl ghrelin in chemotherapy-induced nausea and vomiting Neuropharmacology (IF 4.7) Pub Date : 2024-03-26 Lingqing Yang, Charmaine J.S. Kung, Zengbing Lu, Julia Y.H. Liu, Man Piu Ngan, Takafumi Sakai, Ichiro Sakata, Sze Wa Chan, Longlong Tu, John A. Rudd
Ghrelin and its mimetics have been shown to reduce cisplatin-induced emesis in preclinical studies using ferrets and shrews. This study investigated the effectiveness of ghrelin and des-acyl ghrelin (DAG) in antagonizing cisplatin-induced emesis and physiological changes indicative of nausea in . Animals implanted with radiotelemetry devices were administered ghrelin (0.2, 1.0, and 5.0 μg/day), DAG
-
Oxytocin and social learning in socially anxious men and women Neuropharmacology (IF 4.7) Pub Date : 2024-03-25 Aleya Flechsenhar, Seth M. Levine, Laura E. Müller, Sabine C. Herpertz, Katja Bertsch
This study extended a classic self-referential learning paradigm by investigating the effects of intranasally-administered oxytocin in high and low socially anxious participants during social learning, as a function of social anxiety levels and sex. In a randomized double-blinded design, 160 participants were either given intranasal oxytocin (24 I.U.) or placebo. Subsequently, while lying in an MR
-
A longitudinal MRI and TSPO PET-based investigation of brain region-specific neuroprotection by diazepam versus midazolam following organophosphate-induced seizures Neuropharmacology (IF 4.7) Pub Date : 2024-03-24 Brad A. Hobson, Douglas J. Rowland, Yimeng Dou, Naomi Saito, Zachary T. Harmany, Donald A. Bruun, Danielle J. Harvey, Abhijit J. Chaudhari, Joel R. Garbow, Pamela J. Lein
Acute poisoning with organophosphorus cholinesterase inhibitors (OPs), such as OP nerve agents and pesticides, can cause life threatening cholinergic crisis and . Survivors often experience significant morbidity, including brain injury, acquired epilepsy, and cognitive deficits. Current medical countermeasures for acute OP poisoning include a benzodiazepine to mitigate seizures. Diazepam was long the
-
Ginsenoside Rd enhances blood-brain barrier integrity after cerebral ischemia/reperfusion by alleviating endothelial cells ferroptosis via activation of NRG1/ErbB4-mediated PI3K/Akt/mTOR signaling pathway Neuropharmacology (IF 4.7) Pub Date : 2024-03-22 Sheng Hu, Yuxiang Fei, Chenchen Jin, Jun Yao, Haiyan Ding, Jianing Wang, Chao Liu
-
Tat-NR2B9c attenuates oxidative stress via inhibition of PSD95-NR2B-nNOS complex after subarachnoid hemorrhage in rats Neuropharmacology (IF 4.7) Pub Date : 2024-03-21 Haocheng Zhang, Longbiao Xu, Yezhao He, Zeyu Zhang, Jiahao Zhang, Qian Yu, Yibo Liu, Xiaoyu Wang, Anke Zhang, Kaikai Wang, Yuanjian Fang, Sheng Chen
Oxidative stress plays important roles in the pathogenesis of early brain injury (EBI) after subarachnoid hemorrhage (SAH). Tat-NR2B9c has shown efficacy as a neuroprotective agent in several studies. Here, we identified the neuroprotective role of Tat-NR2B9c after SAH and its related mechanisms. The results showed that Tat-NR2B9c treatment attenuated oxidative stress, therefore alleviated neuronal
-
β2* nAChR sensitivity modulates acquisition of cocaine self-administration in male rats Neuropharmacology (IF 4.7) Pub Date : 2024-03-18 Noah B. Walker, Brenton R. Tucker, Leanne N. Thomas, Andrew E. Tapp, Anna I. Neel, Rong Chen, Sara R. Jones, Ryan M. Drenan
Signaling through nicotinic acetylcholine receptors (nAChRs) plays a role in cocaine reward and reinforcement, suggesting that the cholinergic system could be manipulated with therapeutics to modulate aspects of cocaine use disorder (CUD). We examined the interaction between nAChRs and cocaine reinforcement by expressing a hypersensitive β2 nAChR subunit (β2Leu9′Ser) in the ventral tegmental area of
-
Resveratrol evokes neuroprotective effects and improves foot stance following kainate-induced excitotoxic damage to the mouse spinal cord Neuropharmacology (IF 4.7) Pub Date : 2024-03-16 Benjamín Zylberberg, Martina Poodts, Julieta Roncoroni, M. Florencia Coronel, Graciela L. Mazzone
-
Neuro-modulatory impact of felodipine against experimentally-induced Parkinson's disease: Possible contribution of PINK1-Parkin mitophagy pathway Neuropharmacology (IF 4.7) Pub Date : 2024-03-15 Hadeer O. Abou-Hany, Mohamed El-Sherbiny, Sally Elshaer, Eman Said, Tarek Moustafa
Parkinson's disease (PD) is a prevalent neurodegenerative disorder, characterized by motor and psychological dysfunction. Palliative treatment and dopamine replenishment therapy are the only available therapeutic options. Calcium channel blockers (CCBs) have been reported to protect against several neurodegenerative disorders. The current study was designed to evaluate the neuroprotective impact of
-
PGC-1α in the hippocampus mediates depressive-like and stress-coping behaviours and regulates excitatory synapses in the dentate gyrus in mice Neuropharmacology (IF 4.7) Pub Date : 2024-03-15 Yuhui Deng, Xin Liang, Yue Li, Lin Jiang, Jin Wang, Jing Tang, Jing Li, Yuhan Xie, Kai Xiao, Peilin Zhu, Yijing Guo, Yanmin Luo, Yong Tang
Decreased hippocampal synaptic plasticity is an important pathological change in stress-related mood disorders, including major depressive disorder. However, the underlying mechanism is unclear. PGC-1α, a transcriptional coactivator, is a key factor in synaptic plasticity. We investigated the relationships between changes in hippocampal PGC-1α expression and depressive-like and stress-coping behaviours
-
Ginkgolide B can alleviate spinal cord glymphatic system dysfunction and provide neuroprotection in painful diabetic neuropathy rats by inhibiting matrix metalloproteinase-9 Neuropharmacology (IF 4.7) Pub Date : 2024-03-14 Jiang Li, Shuaiying Jia, Yuehan Song, Wenmei Xu, Jingyan Lin
The glymphatic system plays a crucial role in maintaining optimal central nervous system (CNS) function by facilitating the removal of metabolic wastes. Aquaporin-4 (AQP4) protein, predominantly located on astrocyte end-feet, is a key pathway for metabolic waste excretion. β-Dystroglycan (β-DG) can anchor AQP4 protein to the end-feet membrane of astrocytes and can be cleaved by matrix metalloproteinase
-
Roles of mechanosensitive ion channel PIEZO1 in the pathogenesis of brain injury after experimental intracerebral hemorrhage Neuropharmacology (IF 4.7) Pub Date : 2024-03-13 Min Qi, Ran Liu, Fan Zhang, Zhipeng Yao, Meng-liang Zhou, Xiaochun Jiang, Shizhang Ling
-
Novel pharmacological targets for GABAergic dysfunction in ADHD Neuropharmacology (IF 4.7) Pub Date : 2024-03-08 Anthony S. Ferranti, Deborah J. Luessen, Colleen M. Niswender
Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopment disorder that affects approximately 5% of the population. The disorder is characterized by impulsivity, hyperactivity, and deficits in attention and cognition, although symptoms vary across patients due to the heterogenous and polygenic nature of the disorder. Stimulant medications are the standard of care treatment for ADHD patients
-
Retraction Notice to “Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis” [Neuropharmacology, 107 (2016) 432 – 450] Neuropharmacology (IF 4.7) Pub Date : 2024-03-05 Asmaa M. Teema, Sawsan A. Zaitone, Yasser M. Moustafa
-
Quantitative T2 mapping-based longitudinal assessment of brain injury and therapeutic rescue in the rat following acute organophosphate intoxication Neuropharmacology (IF 4.7) Pub Date : 2024-03-02 Alita Jesal D. Almeida, Brad A. Hobson, Naomi Saito, Donald A. Bruun, Valerie A. Porter, Danielle J. Harvey, Joel R. Garbow, Abhijit J. Chaudhari, Pamela J. Lein
Acute intoxication with organophosphate (OP) cholinesterase inhibitors poses a significant public health risk. While currently approved medical countermeasures can improve survival rates, they often fail to prevent chronic neurological damage. Therefore, there is need to develop effective therapies and quantitative metrics for assessing OP-induced brain injury and its rescue by these therapies. In
-
The mast cells - Cytokines axis in Autism Spectrum Disorder Neuropharmacology (IF 4.7) Pub Date : 2024-03-01 Eleonora Kovacheva, Maria Gevezova, Michael Maes, Victoria Sarafian
Autism Spectrum Disorder (ASD) is a neurodevelopmental disturbance, diagnosed in early childhood. It is associated with varying degrees of dysfunctional communication and social skills, repetitive and stereotypic behaviors. Regardless of the constant increase in the number of diagnosed patients, there are still no established treatment schemes in global practice. Many children with ASD have allergic
-
Retigabine and gabapentin restore channel function and neuronal firing in a cellular model of an epilepsy-associated dominant-negative KCNQ5 variant Neuropharmacology (IF 4.7) Pub Date : 2024-02-29 Johanna Krüger, Holger Lerche
-
Exploring the therapeutic potential of cannabidiol for sleep deprivation-induced hyperalgesia Neuropharmacology (IF 4.7) Pub Date : 2024-02-28 Kangsheng Zhu, Siruan Chen, Xia Qin, Wanjun Bai, Jie Hao, Xiaolei Xu, Han Guo, Hui Bai, Zuxiao Yang, Sheng Wang, Zongmao Zhao, Tengfei Ji, Dezhi Kong, Wei Zhang
-
Opioid modulation of prefrontal cortex cells and circuits Neuropharmacology (IF 4.7) Pub Date : 2024-02-27 Rebecca H. Cole, Khaled Moussawi, Max E. Joffe
Several neurochemical systems converge in the prefrontal cortex (PFC) to regulate cognitive and motivated behaviors. A rich network of endogenous opioid peptides and receptors spans multiple PFC cell types and circuits, and this extensive opioid system has emerged as a key substrate underlying reward, motivation, affective behaviors, and adaptations to stress. Here, we review the current evidence for
-
Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia Neuropharmacology (IF 4.7) Pub Date : 2024-02-25 Tom H. Johnston, Alix M.B. Lacoste, Paula Ravenscroft, Jin Su, Sahar Tamadon, Mahtab Seifi, Anthony E. Lang, Susan H. Fox, Jonathan M. Brotchie, Naomi P. Visanji
Repurposing regulatory agency-approved molecules, with proven safety in humans, is an attractive option for developing new treatments for disease. We identified and assessed the efficacy of 3 drugs predicted by an screen as having the potential to treat -DOPA-induced dyskinesia (LID) in Parkinson's disease.
-
Dopamine-loaded chitosan-coated solid lipid nanoparticles as a promise nanocarriers to the CNS Neuropharmacology (IF 4.7) Pub Date : 2024-02-25 Elena Ortega Martínez, Ma Encarnación Morales Hernández, Julia Castillo-González, Elena González-Rey, Ma Adolfina Ruiz Martínez
Dopamine is unable to access the central nervous system through the bloodstream. Only its precursor can do so, and with an effectiveness below 100% of the dose administered, as it is metabolized before crossing the blood-brain barrier. In this study, we describe a new solid lipid nanocarrier system designed and developed for dopamine. The nanoparticles were prepared by the melt-emulsification method
-
Lights at night mediate depression-like behavioral and molecular phenotypes in a glucocorticoid-dependent manner in male rats Neuropharmacology (IF 4.7) Pub Date : 2024-02-23 Zhenlong Li, Chau-Shoun Lee, Hsien-Yu Peng, Tzer-Bin Lin, Ming-Chun Hsieh, Cheng-Yuan Lai, Dylan Chou
Nocturnal light pollution, an underappreciated mood manipulator, disturbs the circadian rhythms of individuals in modern society. Preclinical and clinical studies have suggested that exposure to lights at night (LANs) results in depression-like phenotypes. However, the mechanism underlying the action of LANs remains unclear. Therefore, this study explored the potential influence of LANs on depression-related
-
Sex-specific effects of sucrose withdrawal on anxiety-like behavior and neuroimmune response Neuropharmacology (IF 4.7) Pub Date : 2024-02-23 Mohit Kumar, Chitralekha Gusain, Babita Bhatt, Roshan Lal, Mahendra Bishnoi
-
Repeated cannabidiol treatment affects neuroplasticity and endocannabinoid signaling in the prefrontal cortex of the Flinders Sensitive Line (FSL) rat model of depression. Neuropharmacology (IF 4.7) Pub Date : 2024-02-23 Luana Barreto Domingos, Heidi Kaastrup Müller, Nicole Rodrigues da Silva, Michaela D. Filiou, Anders Lade Nielsen, Francisco Silveira Guimarães, Gregers Wegener, Sâmia Joca
Delayed therapeutic responses and limited efficacy are the main challenges of existing antidepressant drugs, thereby incentivizing the search for new potential treatments. Cannabidiol (CBD), non-psychotomimetic component of cannabis, has shown promising antidepressant effects in different rodent models, but its mechanism of action remains unclear. Herein, we investigated the antidepressant-like effects
-
-
The NMDA receptor modulator zelquistinel durably relieves behavioral deficits in three mouse models of autism spectrum disorder Neuropharmacology (IF 4.7) Pub Date : 2024-02-22 Mathieu Fonteneau, Agathe Brugoux, Déborah Jaccaz, John E. Donello, Pradeep Banerjee, Julie Le Merrer, Jérôme AJ. Becker
Autism spectrum disorders (ASD) are complex neurodevelopmental disorders characterized by deficient social communication and interaction together with restricted, stereotyped behaviors. Currently approved treatments relieve comorbidities rather than core symptoms. Since excitation/inhibition balance and synaptic plasticity are disrupted in ASD, molecules targeting excitatory synaptic transmission appear
-
Sex differences in the rodent medial prefrontal cortex – What Do and Don't we know? Neuropharmacology (IF 4.7) Pub Date : 2024-02-20 M.A. Laine, E.M. Greiner, R.M. Shansky
The prefrontal cortex, particularly its medial subregions (mPFC), mediates critical functions such as executive control, behavioral inhibition, and memory formation, with relevance for everyday functioning and psychopathology. Despite broad characterization of the mPFC in multiple model organisms, the extent to which mPFC structure and function vary according to an individual's sex is unclear – a knowledge
-
Pharmacological blockage of NOP receptors decreases ventral tegmental area dopamine neuronal activity through GABAB receptor-mediated mechanism Neuropharmacology (IF 4.7) Pub Date : 2024-02-15 Michele Petrella, Anna Maria Borruto, Lorenzo Curti, Ana Domi, Esi Domi, Li Xu, Estelle Barbier, Alice Ilari, Markus Heilig, Friedbert Weiss, Guido Mannaioni, Alessio Masi, Roberto Ciccocioppo
The Nociceptin/Orphanin FQ (N/OFQ) peptide and its receptor NOP are highly expressed within several regions of the mesolimbic system, including the ventral tegmental area (VTA). Evidence indicates that the N/OFQ-NOP receptor system is involved in reward processing and historically it has been proposed that activation of NOP receptors attenuates the motivation for substances of abuse. However, recent
-
Postweaning stress affects behavior, brain and gut microbiota of adolescent mice in a sex-dependent manner Neuropharmacology (IF 4.7) Pub Date : 2024-02-13 Xueyong Yin, Ye Zhao, Shuang Wang, Hao Feng, Xinyue He, Xincheng Li, Xiaoyu Liu, Hengtai Lu, Di Wen, Yun Shi, Haishui Shi
Aggression is an instinctive behavior that has been reported to be influenced by early-life stress. However, the potential effects of acute stress during the postweaning period, a key stage for brain development, on defensive aggression and the associated mechanism remain poorly understood. In the present study, aggressive behaviors were evaluated in adolescent mice exposed to postweaning stress. Serum
-
MUFA synthesis and stearoyl-CoA desaturase as a new pharmacological target for modulation of lipid and alpha-synuclein interaction against Parkinson's disease synucleinopathy Neuropharmacology (IF 4.7) Pub Date : 2024-02-10 Joanna Kula, Katarzyna Z. Kuter
-
Impact of caloric restriction on oxidative stress and key glycolytic enzymes in the cerebral cortex, liver and kidney of old and middle-aged mice Neuropharmacology (IF 4.7) Pub Date : 2024-02-09 Myroslava V. Vatashchuk, Viktoriia V. Hurza, Nadiia Stefanyshyn, Maria M. Bayliak, Dmytro V. Gospodaryov, Olga Garaschuk, Volodymyr I. Lushchak
Caloric restriction (CR) is proposed as a strategy to prevent age-related alterations as impaired glucose metabolism and intensification of oxidative stress. In this study, we examined effects of aging and CR on the activities of glycolytic enzymes and parameters of oxidative stress in the cerebral cortex, liver, and kidney of middle-aged (9 months old) and old (18 months old) C57BL6/N mice. Control
-
Sleep loss disrupts decision-making ability and neuronal cytomorphology in zebrafish and the effects are mediated by noradrenaline acting on α1-adrenoceptor Neuropharmacology (IF 4.7) Pub Date : 2024-02-07 Kumar Abhishek, Birendra Nath Mallick
Sleep is an instinct behavior, and its significance and functions are still an enigma. It is expressed throughout one's life and its loss affects psycho-somatic and physiological processes. We had proposed that it might maintain a fundamental property of the neurons and the brain. In that context, it was shown that sleep, rapid eye movement sleep (REMS) in particular, by regulating noradrenaline (NA)
-
Optogenetic stimulation of corticostriatal circuits improves behavioral flexibility in mice with prenatal alcohol exposure Neuropharmacology (IF 4.7) Pub Date : 2024-02-07 Valentina Licheri, Jayapriya Chandrasekaran, Johnny A. Kenton, Clark W. Bird, C. Fernando Valenzuela, Jonathan L. Brigman
Fetal alcohol spectrum disorder (FASD) is the most common preventable form of developmental and neurobehavioral disability. Animal models have demonstrated that even low to moderate prenatal alcohol exposure (PAE) is sufficient to impair behavioral flexibility in multiple domains. Previously, utilizing a moderate limited access drinking in the dark paradigm, we have shown that PAE 1) impairs touchscreen
-
Corrigendum to “Oxytocinergic neurons, but not oxytocin, are crucial for male penile erection” [Neuropharmacol. 235 (2023) 109576] Neuropharmacology (IF 4.7) Pub Date : 2024-02-06 Yu-Xiang Wen, Lin-Yao Fan, An-Yong Yang, Yan-Chufei Zhang, Chang Xu, Zi-Hui Wang, Wen-Jiong Xie, Yang Lu, Xiao-Yang Zhang, Jing-Ning Zhu, Anyang Sun, Liang Li, Qi-Peng Zhang
-
Sex differences in risk-based decision-making and the modulation of risk preference by dopamine-2 like receptors in rats Neuropharmacology (IF 4.7) Pub Date : 2024-02-06 Samantha M. Ayoub, Avraham M. Libster, Samuel A. Barnes, Stephanie C. Dulawa, Jared W. Young
Heightened risk-based decision-making is observed across several neuropsychiatric disorders including schizophrenia, bipolar disorder, and Parkinson's disease, yet no treatments exist that effectively normalize this aberrant behavior. Preclinical risk-based decision-making paradigms have identified the important modulatory roles of dopamine and sex in the performance of such tasks, though specific
-
DHEC mesylate attenuates pathologies and aberrant bisecting N-glycosylation in Alzheimer's disease models Neuropharmacology (IF 4.7) Pub Date : 2024-02-06 Yue Wang, Yiming Cao, Hongfei Huang, Yue Xue, Song Chen, Xiangdong Gao
Tremendous progress has been made to develop the therapy of Alzheimer's disease (AD). Existing several anti-AD remedies, with certain limitations, are far from adequate. Evidence suggests that dihydroergocristine (DHEC) mesylate, one of the main components of Ergoloid mesylates, can reduce the production of amyloid-β in vitro. However, the therapeutic effect of DHEC mesylate in AD and its underlying
-
Effects of the adenosine A2A receptor antagonist KW6002 on the dopaminergic system, motor performance, and neuroinflammation in a rat model of Parkinson's disease Neuropharmacology (IF 4.7) Pub Date : 2024-02-05 Kavya Prasad, Erik F.J. de Vries, Esther van der Meiden, Rodrigo Moraga-Amaro, Daniel Aaron Vazquez-Matias, Lara Barazzuol, Rudi A.J.O. Dierckx, Aren van Waarde
-
Adolescent intermittent ethanol exposure decreases perineuronal nets in the hippocampus in a sex dependent manner: Modulation through pharmacological inhibition of RPTPβ/ζ Neuropharmacology (IF 4.7) Pub Date : 2024-01-29 Milagros Galán-Llario, Esther Gramage, Alba García-Guerra, Abraham B. Torregrosa, Ani Gasparyan, Daniela Navarro, Francisco Navarrete, María Salud García-Gutiérrez, Jorge Manzanares, Gonzalo Herradón
-
Novel aspects of signal processing in lamina I Neuropharmacology (IF 4.7) Pub Date : 2024-01-28 Boris V. Safronov, Peter Szucs
The most superficial layer of the spinal dorsal horn, lamina I, is a key element of the nociceptive processing system. It contains different types of projection neurons (PNs) and local-circuit neurons (LCNs) whose functional roles in the signal processing are poorly understood. This article reviews recent progress in elucidating novel anatomical features and physiological properties of lamina I PNs
-
-
Melanocortin agonism in a social context selectively activates nucleus accumbens in an oxytocin-dependent manner Neuropharmacology (IF 4.7) Pub Date : 2024-01-20 Charles L. Ford, Anna A. McDonough, Kengo Horie, Larry J. Young
-
Potentiation of prefrontal cortex dopamine function by the novel cognitive enhancer d-govadine Neuropharmacology (IF 4.7) Pub Date : 2024-01-18 Maya O. Nesbit, Soyon Ahn, Haiyan Zou, Stan B. Floresco, Anthony G. Phillips
Cognitive impairment is a debilitating feature of psychiatric disorders including schizophrenia, mood disorders and substance use disorders for which there is a substantial lack of effective therapies. d-Govadine (d-GOV) is a tetrahydroprotoberberine recently shown to significantly enhance working memory and behavioural flexibility in several prefrontal cortex (PFC)-dependent rodent tasks. d-GOV potentiates
-
Valence-dependent effects of neuropeptide Y on the expression of conditioned fear and anxiety-like behavior: Involvement of the bed nucleus of the stria terminalis Neuropharmacology (IF 4.7) Pub Date : 2024-01-11 Johannes Kornhuber, Iulia Zoicas
Neuropeptide Y (NPY) has anxiolytic-like effects and facilitates the extinction of cued and contextual fear in rodents. We have previously shown that intracerebroventricular administration of NPY reduces the expression of social fear via simultaneous activation of Y1 and Y2 receptors in a mouse model of social fear conditioning (SFC). In the present study, we investigated whether the anteroventral
-
Inhibition of resurgent Na+ currents by rufinamide Neuropharmacology (IF 4.7) Pub Date : 2024-01-14 Jian-Lin Chen, Chung-Chin Kuo
Na+ channels are essential for the genesis of action potentials in most neurons. After opening by membrane depolarization, Na+ channels enter a series of inactivated states (e.g. the fast, intermediate, and slow inactivated states; or If, Ii, and Is). The inactivated Na+ channel may recover via the open state upon membrane repolarization, giving rise to “resurgent” Na+ currents which could be critical
-
Stress inoculation during adolescence attenuates social stress-induced increase in ethanol intake in adult male mice Neuropharmacology (IF 4.7) Pub Date : 2024-01-08 Marina D. Reguilón, Carmen Manzanedo, José Miñarro, Marta Rodríguez-Arias
Social stress exposure heightens the risk of substance abuse disorder development, especially when endured during adolescence, influencing long-term mental health. This study investigates early-life stress's potential to confer resilience against later-life stressors. To investigate this hypothesis, we examined the impact of a single social defeat (SD) incident during adolescent mice's lives on subsequent
-
-
Roflupram alleviates autophagy defects and reduces mutant hSOD1-induced motor neuron damage in cell and mouse models of amyotrophic lateral sclerosis Neuropharmacology (IF 4.7) Pub Date : 2024-01-12 Di Huo, Weiwei Liang, Di Wang, Qiaochu Liu, Hongyong Wang, Ying Wang, Chunting Zhang, Chaohua Cong, Xiaoli Su, Xingli Tan, Wenmo Zhang, Ling Han, Dongmei Zhang, Ming Wang, Honglin Feng
Amyotrophic lateral sclerosis (ALS) is a fatal and incurable disease involving motor neuron (MN) degeneration and is characterized by ongoing myasthenia and amyotrophia in adults. Most ALS patients die of respiratory muscle paralysis after an average of 3–5 years. Defective autophagy in MNs is considered an important trigger of ALS pathogenesis. Roflupram (ROF) was demonstrated to activate autophagy
-
Dynamic effects of ventral hippocampal NRG3/ERBB4 signaling on nicotine withdrawal-induced responses Neuropharmacology (IF 4.7) Pub Date : 2024-01-09 Miranda L. Fisher, Emily R. Prantzalos, Bernadette O'Donovan, Tanner L. Anderson, Pabitra K. Sahoo, Jeffery L. Twiss, Pavel I. Ortinski, Jill R. Turner
Tobacco smoking remains a leading cause of preventable death in the United States, with approximately a 5% success rate for smokers attempting to quit. High relapse rates have been linked to several genetic factors, indicating that the mechanistic relationship between genes and drugs of abuse is a valuable avenue for the development of novel smoking cessation therapies. For example, various single
-
Protective role of madecassoside from Centella asiatica against protein L-isoaspartyl methyltransferase deficiency-induced neurodegeneration Neuropharmacology (IF 4.7) Pub Date : 2024-01-03 Zicheng Ling, Sirui Zhou, Yancheng Zhou, Wanyu Zhong, Zhonghao Su, Zhenxia Qin
-
BNC210, a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor, demonstrates anxiolytic- and antidepressant-like effects in rodents Neuropharmacology (IF 4.7) Pub Date : 2024-01-06 Susan M. O'Connor, Brad E. Sleebs, Ian P. Street, Bernard L. Flynn, Jonathan B. Baell, Carolyn Coles, Nurul Quazi, Dharam Paul, Etienne Poiraud, Bertrand Huyard, Stephanie Wagner, Emile Andriambeloson, Errol B. de Souza
This work describes the characterization of BNC210 (6-[(2,3-dihydro-1H-inden-2-yl)amino]-1-ethyl-3-(4-morpholinylcarbonyl)-1,8-naphthyridin-4(1H)-one), a selective, small molecule, negative allosteric modulator (NAM) of α7 nicotinic acetylcholine receptors (α7 nAChR). With the aim to discover a non-sedating, anxiolytic compound, BNC210 was identified during phenotypic screening of a focused medicinal
-
Requisite role of dorsal raphé in contextual cocaine-memory reconsolidation Neuropharmacology (IF 4.7) Pub Date : 2024-01-03 J.L. Ritchie, S. Qi, R.J. Christian, M.J. Greenwood, H.I. Grenz, S.E. Swatzell, P.J. Krych, R.A. Fuchs
Memory reconsolidation is a process by which labile drug memories are restabilized in long-term memory stores, permitting their enduring control over drug-seeking behaviors. In the present study, we investigated the involvement of the dorsal raphé nuclei (DRN) in cocaine-memory reconsolidation. Sprague-Dawley rats (male, female) were trained to self-administer cocaine in a distinct environmental context
-
Phosphoproteomics implicates glutamatergic and dopaminergic signalling in the antidepressant-like properties of the iron chelator deferiprone Neuropharmacology (IF 4.7) Pub Date : 2024-01-04 Volkan Uzungil, Sandra Luza, Carlos M. Opazo, Isaline Mees, Shanshan Li, Ching-Seng Ang, Nicholas A. Williamson, Ashley I. Bush, Anthony J. Hannan, Thibault Renoir
Background Current antidepressants have limitations due to insufficient efficacy and delay before improvement in symptoms. Polymorphisms of the serotonin transporter (5-HTT) gene have been linked to depression (when combined with stressful life events) and altered response to selective serotonergic reuptake inhibitors. We have previously revealed the antidepressant-like properties of the iron chelator
-
Cannabidiol as a potential cessation therapeutic: Effects on intravenous nicotine self-administration and withdrawal symptoms in mice Neuropharmacology (IF 4.7) Pub Date : 2024-01-03 Samantha N. Cheeks, Belle Buzzi, Ashley Valdez, Allison S. Mogul, M. Imad Damaj, Christie D. Fowler
Cigarette smoking remains a leading cause of preventable disease and death worldwide. Due to the devastating negative health effects of smoking, many users attempt to quit, but few are successful in the long-term. Thus, there is a critical need for novel therapeutic approaches. In these investigations, we sought to examine whether cannabidiol (CBD) has the potential to be repurposed as a nicotine cessation